Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invivyd ( (IVVD) ) has shared an update.
On September 22, 2025, Invivyd, Inc. appointed Paul B. Bolno, M.D. as a director and member of the Compensation Committee, following Christine Akinc’s resignation. Dr. Bolno’s appointment is expected to bolster Invivyd’s efforts in advancing its pipeline for viral infectious diseases. Additionally, Invivyd regained compliance with Nasdaq’s minimum bid price requirement, resolving a previous non-compliance issue.
The most recent analyst rating on (IVVD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop antibodies and received emergency use authorization from the U.S. FDA for a monoclonal antibody in its pipeline.
Average Trading Volume: 5,579,020
Technical Sentiment Signal: Buy
Current Market Cap: $237.8M
See more data about IVVD stock on TipRanks’ Stock Analysis page.